Veracyte licenses gene signature for idiopathic pulmonary fibrosis

By LabPulse.com staff writers

April 23, 2020 -- Veracyte has licensed exclusive rights to a 52-gene signature for idiopathic pulmonary fibrosis (IPF) from Yale University and plans to develop a blood test for use on its diagnostics platform.

Developed by Yale's Dr. Naftali Kaminski and colleagues, the test predicts rapid disease progression associated with IPF. Experience with the gene signature in a multicenter study was published by Kaminski et al in Lancet Respiratory Medicine (November 2017, Vol. 11, pp. 857-868). Some 200,000 patients in the U.S. and Europe are evaluated for IPF and other interstitial lung diseases every year and knowing the severity of the disease could help guide them to the right treatments, the company noted.

The test will be designed for use on Veracyte's nCounter FLEX Analysis system and will complement the company's Envisia Genomic Classifier, which is designed to help distinguish IPF from other similar diseases. Veracyte licensed exclusive global rights to the nCounter diagnostics platform from NanoString at the end of last year in a $50 million deal.

Veracyte has also established an agreement with Yale involving genomics research related to interstitial lung diseases at Kaminski's lab.

Veracyte licenses NanoString diagnostic platform in $50M deal
Veracyte is set to pay $50 million -- $40 million in cash and the rest in common stock -- for an exclusive global license to the NanoString...
Veracyte nasal swab test holds its own in lung cancer detection
Veracyte said the accuracy of its investigational nasal swab genomic classifying test rivals the clinical standard for lung nodule assessment and has...
Veracyte validates Afirma XA in thyroid cancer
Veracyte published data in Frontiers in Endocrinology on September 11 supporting the utility of its Afirma Expression Atlas (XA) test for identifying...
Popular rule-out test for thyroid cancer draws scrutiny
Researchers are questioning whether a commonly used gene expression classifier test for evaluating indeterminate thyroid nodules lives up to expectations,...

Copyright © 2020 LabPulse.com

Last Updated np 4/23/2020 2:37:36 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email